U.S. Stock Market Midday Update
Biohaven Pharmaceutical rose 8.02%. Based on recent key news:
<ol>
<li>
On January 12, Biohaven Ltd. introduced its latest degradation platform during a company presentation, particularly highlighting the potential of BHV-1400 in treating IgA nephropathy. This news boosted market confidence in its innovative drugs, driving the stock price up.
</li>
<li>
On January 12, Biohaven announced the successful initiation of subcutaneous administration of BHV-1510, marking the first clinical subcutaneous delivery of this Trop2 ADC, which showed good bioavailability and tumor reduction effects. This technological advancement may improve patient experience, enhance safety and efficacy, and stimulate stock price growth.
</li>
<li>
On January 12, Biohaven's FGFR3 ADC BHV-1530 demonstrated early clinical activity in urothelial carcinoma, with no dose-limiting toxicity observed and good safety profile. This clinical trial progress further solidified Biohaven's leading position in the ADC field, boosting the stock price. The biopharmaceutical industry is actively developing innovative drugs, with significant capital inflow.
</li>
</ol>
Top Stocks by Industry Trading Volume
AbbVie rose 0.20%. Based on recent key news:
<ol>
<li>
On January 13, AbbVie signed an exclusive licensing agreement with Rongchang Biologics to obtain development, production, and commercialization rights for RC148 outside of Greater China. Upon the agreement's effectiveness, AbbVie will pay a $650 million upfront payment and is eligible for milestone payments of up to $4.95 billion. This collaboration enhances AbbVie's positioning in the oncology drug sector, driving the stock price up.
</li>
<li>
On January 13, AbbVie reached an agreement with the U.S. government to commit $100 billion over the next decade for research and capital investment in the U.S. in exchange for tariff reductions. This agreement aims to improve drug accessibility and reduce burdens, further solidifying AbbVie's position in the U.S. market, boosting the stock price.
</li>
<li>
On January 12, AbbVie announced a collaboration with Rongchang Biologics to develop experimental therapies for solid tumors, with a total value of up to $4.95 billion. This collaboration agreement demonstrates AbbVie's proactive positioning in innovative drug development, enhancing market confidence and driving the stock price up. The industry is performing well overall, with significant capital inflow, and policy changes need to be monitored.
</li>
</ol>
Moderna rose 2.27%. Based on recent key news:
<ol>
<li>
On January 12, Moderna raised its revenue forecast for 2025 to $1.9 billion, slightly above analysts' expectations of $1.89 billion, driving the stock price up. The company also reduced its operating expense forecast for 2025, further boosting market confidence. Source: Reuters
</li>
<li>
On January 14, Moderna's stock price rose over 15% due to its COVID-19 business performing better than expected and further cost reductions. The company expects to break even by 2028. Source: Bloomberg
On January 14, technical analysis showed that Moderna's stock price broke through a long-term pattern, forming a &#34;golden cross&#34; signal, with strong momentum, and the stock price is expected to continue rising. Source: Barron’s The biotechnology sector performed strongly, with significant capital inflows.
</li>
</ol>
Biogen fell 4.79%. Based on recent news,
<ol>
<li>
On January 14, Biogen expected fourth-quarter research and development expenses and milestone costs to total approximately $222 million, resulting in a decrease of about $1.26 in earnings per share. Following this news, the stock price dropped by 3.95%.
</li>
<li>
On January 15, Biogen anticipated $222 million in expenses related to acquisition costs for the fourth quarter, impacting net income by about $1.26 per share. This news led to a 5% decline in the stock price.
</li>
<li>
On January 13, Biogen's SPINRAZA high-dose regimen was approved in Japan and is under review by the U.S. FDA, with a decision expected on April 3. Although this news is beneficial for the company in the long term, it failed to boost the stock price in the short term. The biotechnology industry has been volatile recently, and investors should exercise caution.
</li>
</ol>
Stocks ranked at the top of the industry by market capitalization
Amgen rose 0.84%, with a market capitalization of $176 billion. Based on recent key news:
<ol>
<li>
On January 14, Goldman Sachs pointed out that Amgen's next-generation weight loss drug MariTide could be a significant catalyst for upward stock price movement. Goldman Sachs believes that Amgen's price-to-earnings ratio is significantly below the industry average, with a target price of $400, expecting about 30% upside potential. The rising global obesity rate has driven demand for weight loss drugs, and the efficacy and market potential of MariTide are viewed positively.
</li>
<li>
On January 13, Amgen announced a collaboration with Ro to conduct real-world studies covering GLP-1. This collaboration aims to identify unmet needs through observational studies and assist in future treatment development and innovation.
</li>
<li>
On January 12, Amgen's MariTide drug showed significant blood sugar and weight loss effects in a 24-week study. Most participants maintained weight loss in a 52-week extension study, and the drug was well tolerated. The biotechnology sector is valued lower than the S&amp;P 500 index
</li>
</ol>

BHVN

Biohaven Pharmaceutical rose 8.02%; AbbVie rose 0.20%, with a transaction volume of USD 971 million; Moderna rose 2.27%, with a transaction volume of USD 635 million; Biogen fell 4.79%, with a transaction volume of USD 480 million; Amgen rose 0.84%, with a market value of USD 176 billion

U.S. stock market midday update: Biohaven Pharmaceutical up 8.02%, progress in innovative drugs boosts market confidence